Skip to main content

Table 4 Clinical characteristics of patients whose tumors acquired CDKN2A deletions at recurrence/progression

From: Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas

Patient ID # Age at diagnosis (years) Sex Tumor Pathologic classification Tumor location Metastatic disease at diagnosis Extent of surgery #1 Time to first progression (months) Time to surgery #2 (months) Treatment received between diagnosis and gain of CDKN2A deletion Current status (months from diagnosis to last follow-up)
1 5 F Pilocytic astrocytoma Diencephalic (hypothalamic/optic pathway) No STR 20 26 Chemotherapy (carboplatin, temozolomide) Alive (104)
2 12 M Pilocytic astrocytoma Diencephalic (hypothalamic/optic pathway) No STR 2 27 Irradiation photon (50.4 Gy)] Alive (116)
4 0.8 F Pilomyxoid astrocytoma Diencephalic (hypothalamic) No Biopsy 3.5 7 Chemotherapy (carboplatin/vincristine, vinblastine, temozolomide, trametinib), additional debulking surgery Alive (58)
15 1 M Pilocytic astrocytoma Posterior fossa No STR 19 19 Surgery only Alive (93)
18 5 M Pilocytic astrocytoma Posterior fossa No STR 17 17 Surgery only Alive (182)
26 15 M Pilocytic astrocytoma Cerebrum (Right temporal-parietal) No STR (biopsy, then STR 1 week later) 5.5 5.5 Surgery only Deceased (91; Drug overdose, unrelated to disease)
41 0.4 F Desmoplastic infantile ganglioglioma Cerebrum (Right frontal) No STR 4 8 Chemotherapy (carboplatin/vincristine) Alive (94)